LB PHARMACEUTICALS INC
No SEC Form 4 filings for $LBRX in the last 30 days.
See all $LBRX insider activity →Analysts reiterated Buy ratings on SpaceX (SPCX) with a $250.00 target, Six Flags (FUN) with a $17.00 target, and LB Pharmaceuticals (LBRX) with a $53.00 target. Consensus targets suggest 61.5%, 126.6%, and 58.0% upside respectively.
Stifel maintained a Buy rating and $53 price target for LB Pharmaceuticals (LBRX) after meetings with executives. LBRX shares have risen 156% over the past year. The company is preparing for a phase 3 schizophrenia trial readout for LB-102 in 2027. Analysts cite potential market opportunities in schizophrenia and Alzheimer's. LBRX is not expected to be profitable this year, but has a strong financial health rating.
JPMorgan Chase reduced its stake in LB Pharmaceuticals (LBRX) by 95,503 shares at $38.38 each, retaining 1.4M shares. LBRX, a biotech firm, has no revenue and operates at a loss. Its stock is down 11.41% since the trade, currently at $34.00. JPMorgan's remaining stake represents 4.30% of its portfolio.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning LBRX (LB PHARMACEUTICALS INC). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent LBRX coverage spans financial news, corporate actions and technology.
Potential upside as analysts raise targets.
Analyst upgrade may support modest upside.
Institutional sell may trigger short-term price weakness.
Analyst upgrades suggest upside potential for LBRX.
Positive preclinical results support LB-102's mechanism, likely driving buying interest.
AlphAI scores every news story that mentions LBRX with an AI model for sentiment and relevance, and aggregates insider trades from LB PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts reiterated Buy ratings on SpaceX (SPCX) with a $250.00 target, Six Flags (FUN) with a $17.00 target, and LB Pharmaceuticals (LBRX) with a $53.00 target. Consensus targets suggest 61.5%, 126.6%, and 58.0% upside respectively.
2 min readStifel maintained a Buy rating and $53 price target for LB Pharmaceuticals (LBRX) after meetings with executives. LBRX shares have risen 156% over the past year. The company is preparing for a phase 3 schizophrenia trial readout for LB-102 in 2027. Analysts cite potential market opportunities in schizophrenia and Alzheimer's. LBRX is not expected to be profitable this year, but has a strong financial health rating.
2 min readJPMorgan Chase reduced its stake in LB Pharmaceuticals (LBRX) by 95,503 shares at $38.38 each, retaining 1.4M shares. LBRX, a biotech firm, has no revenue and operates at a loss. Its stock is down 11.41% since the trade, currently at $34.00. JPMorgan's remaining stake represents 4.30% of its portfolio.
2 min readH.C. Wainwright maintained a Buy rating and $60 price target for LB Pharmaceuticals (LBRX), citing positive preclinical data on LB-102. The stock has gained 141% over the past year but may be overvalued. Other analysts also reiterated Buy ratings with higher price targets, highlighting LB-102's potential in treating neuropsychiatric disorders. LBRX trades at $37.22, offering 61% upside to the $60 target.
2 min readGuggenheim reiterated a Buy rating and $80.00 price target on LB Pharmaceuticals (LBRX) after new preclinical study results for LB-102. The stock has risen 141% in the past year to $37.22. The company has more cash than debt. Analysts estimate U.S. peak sales of $2.1B for schizophrenia and $1.3B for bipolar depression. Other analysts also raised price targets and ratings.
2 min readLB Pharmaceuticals (LBRX) presented preclinical and clinical data on LB-102 at the ECNP congress. The data showed LB-102's potential to modulate dopamine signaling and improve cognitive performance in schizophrenia. The company also detailed ongoing Phase 3 trials for schizophrenia and a Phase 2 trial for bipolar depression.
2 min readLB Pharmaceuticals granted its new CMO and CFO options for 200,000 shares each at $37.22, vesting over 4 years. The company is in early-stage management development as it advances its neuromedicine pipeline.
1 min readLB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer NEW YORK, September 15, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commerciali
1 min readLB Pharmaceuticals (LBRX) appointed Joseph Miller as CFO, bringing 20+ years of biotech financial experience. CEO Heather Turner highlighted upcoming NOVA-2 trial results and potential schizophrenia drug launch. Shares traded 0.75% lower at $49.11 in pre-market.
1 min readLB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing hig
1 min read
